
|Articles|July 15, 2004
Outcomes favorable in 2-year experience with silicone IOL
San Diego - Two-year follow-up of eyes with the ClariFlex with OptiEdge silicone IOL (AMO) implanted show that the second-generation silicone IOL with its novel edge design is performing well. Furthermore, risk of posterior capsular opacification (PCO) and glare was minimal, according to the results of a study presented by Elizabeth A. Davis, MD, FACS, at the annual meeting of the American Society of Cataract and Refractive Surgery.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Study identifies 6 key genes linking air pollution to dry eye disease
2
4DMT releases positive interim 1.5- to 3.5-year data from phase 1/2 PRISM trial
3
Q&A: Karolinne M. Rocha discusses the IOL and patient tolerance of residual astigmatism
4
Nanoscope Therapeutics releases positive long-term safety results from EXTEND study
5


















































.png)


